In multidisciplinary guidelines issued by the American Society of Regional Anesthesia and Pain Medicine and publishe ...

The first comprehensive guidelines dedicated to minimizing infections in patients undergoing surgeries and procedures ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The Centers for Disease Control and Prevention (CDC) recently issued new guidelines for pain management treatment and ...

Learn about the latest recommendations from ASRA Pain Medicine to reduce infectious complications in regional anesthesia and pain procedures.

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

As opioid pain medications continue being prescribed for chronic and severe pain, understanding their risks becomes ...

Integrating lifestyle care into low back pain management resulted in greater improvements in disability, weight loss and ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction ...

A study has found that integrating lifestyle support into chronic back pain treatment helps reduce disability and improves quality of life.

The following is a summary of “Pain Assessment and Management in Oncological Practice: A Survey from the Italian Network of ...